Pennsylvania | 33-0272839 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
Large accelerated filer | o | Accelerated filer | o | |||
Non-accelerated filer | x | Smaller reporting company | x | |||
Emerging growth company | o |
TABLE OF CONTENTS | ||
Page | ||
Item I. | ||
Condensed Consolidated Balance Sheets as of September 30, 2019 and June 30, 2019 (Unaudited) | ||
Item 2. | ||
Item 3. | ||
Item 4. | ||
Item 6. |
ESCALON MEDICAL CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | |||||||
September 30, 2019 | June 30, 2019 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 415,818 | $ | 409,743 | |||
Restricted cash | 253,404 | 253,135 | |||||
Accounts receivable, net | 1,355,105 | 1,496,105 | |||||
Inventories | 1,900,680 | 1,878,860 | |||||
Other current assets | 227,663 | 223,078 | |||||
Total current assets | 4,152,670 | 4,260,921 | |||||
Property and equipment, net | 60,903 | 67,896 | |||||
Right-of-use assets | 1,055,682 | — | |||||
Trademarks and trade names | 605,006 | 605,006 | |||||
License, net | 136,787 | 141,700 | |||||
Other long term assets | 62,788 | 51,915 | |||||
Total assets | $ | 6,073,836 | $ | 5,127,438 | |||
LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Line of credit | $ | 201,575 | $ | 201,575 | |||
Current portion of note payable | 3,491 | 3,401 | |||||
Accounts payable | 691,361 | 666,510 | |||||
Accrued expenses | 619,413 | 656,707 | |||||
Related party accrued interest | 112,389 | 112,389 | |||||
Current portion of post-retirement benefits (related party) | 8,491 | 101,891 | |||||
Current portion of operating lease liabilities | 281,085 | — | |||||
Deferred revenue | 426,470 | 426,803 | |||||
Liabilities of discontinued operations | 87,494 | 90,933 | |||||
Total current liabilities | 2,431,769 | 2,260,209 | |||||
Note payable, net of current portion | 13,984 | 14,896 | |||||
Operating lease liabilities, net of current portion | 844,471 | — | |||||
Accrued post-retirement benefits, net of current portion (related party) | — | 690,094 | |||||
Total long-term liabilities | 858,455 | 704,990 | |||||
Total liabilities | 3,290,224 | 2,965,199 | |||||
Shareholders' equity: | |||||||
Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized; 2,000,000 shares issued and outstanding (liquidation value of $728,974 and $715,968) | 645,000 | 645,000 | |||||
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding | 7,415 | 7,415 | |||||
Additional paid-in capital | 69,702,043 | 69,702,043 | |||||
Accumulated deficit | (67,570,846 | ) | (68,192,219 | ) | |||
Total shareholders’ equity | 2,783,612 | 2,162,239 | |||||
Total liabilities and shareholders’ equity | $ | 6,073,836 | $ | 5,127,438 |
ESCALON MEDICAL CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) | ||||||||
For the Three Months Ended September 30, | ||||||||
2019 | 2018 | |||||||
Net revenues: | ||||||||
Products | $ | 2,052,779 | $ | 2,022,383 | ||||
Service plans | 235,209 | 236,000 | ||||||
Revenues, net | 2,287,988 | 2,258,383 | ||||||
Costs and expenses: | ||||||||
Cost of goods sold | 1,176,670 | 1,203,133 | ||||||
Marketing, general and administrative | 999,427 | 1,002,237 | ||||||
Research and development | 245,638 | 96,408 | ||||||
Total costs and expenses | 2,421,735 | 2,301,778 | ||||||
Loss from operations | (133,747 | ) | (43,395 | ) | ||||
Other income (expense) | ||||||||
Other income | 758,021 | — | ||||||
Interest income | 1,083 | 2,510 | ||||||
Interest expense | (3,984 | ) | (6,851 | ) | ||||
Total other income, net | 755,120 | (4,341 | ) | |||||
Net income (loss) | 621,373 | (47,736 | ) | |||||
Undeclared dividends on preferred stocks | 13,006 | 13,005 | ||||||
Net income (loss) applicable to common shareholders | $ | 608,367 | $ | (60,741 | ) | |||
Net income (loss) per share | ||||||||
Basic income (loss) per share | $ | 0.08 | $ | (0.01 | ) | |||
Diluted income (loss) per share | $ | 0.05 | $ | (0.01 | ) | |||
Weighted average shares—basic | 7,415,329 | 7,415,329 | ||||||
Weighted average shares—diluted | 12,188,449 | 7,415,329 |
ESCALON MEDICAL CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2019 AND SEPTEMBER 30, 2018 (UNAUDITED) | |||||||||||||||||||||||||||||
Series A Convertible Preferred Stock | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total Shareholders’ Equity | |||||||||||||||||||||||||
Shares | Amount | Shares | Amount | ||||||||||||||||||||||||||
Balance at June 30, 2019 | 2,000,000 | $ | 645,000 | 7,415,329 | $ | 7,415 | $ | 69,702,043 | $ | (68,192,219 | ) | $ | 2,162,239 | ||||||||||||||||
Net income | — | — | — | — | — | — | 621,373 | 621,373 | |||||||||||||||||||||
Balance at September 30, 2019 | 2,000,000 | $ | 645,000 | 7,415,329 | $ | 7,415 | — | $ | 69,702,043 | — | $ | (67,570,846 | ) | — | $ | 2,783,612 |
Series A Convertible Preferred Stock | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total Shareholders’ Equity | ||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||
Balance at June 30, 2018 | — | $ | — | 7,415,329 | $ | 7,415 | $ | 69,702,043 | $ | (67,942,203 | ) | $ | 2,412,255 | |||||||||||||||||
Net loss | — | — | — | — | — | (47,736 | ) | (47,736 | ) | |||||||||||||||||||||
Balance at September 30, 2018 | — | — | $ | — | 7,415,329 | $ | 7,415 | — | $ | 69,702,043 | — | $ | (67,989,939 | ) | — | $ | 2,364,519 |
ESCALON MEDICAL CORP. AND SUBSIDIARIES | |||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
(UNAUDITED) | |||||||
For the Three Months Ended September 30, | |||||||
2019 | 2018 | ||||||
Cash Flows from Operating Activities: | |||||||
Net income (loss) | $ | 621,373 | $ | (47,736 | ) | ||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||||||
Depreciation and amortization | 11,906 | 13,186 | |||||
Non cash lease expense | 82,195 | — | |||||
Non cash post-retirement benefits adjustment | (758,021 | ) | — | ||||
Change in operating assets and liabilities: | |||||||
Accounts receivable | 141,000 | (35,343 | ) | ||||
Inventories | (21,820 | ) | 58,232 | ||||
Other current assets | (4,585 | ) | (7,427 | ) | |||
Other long-term assets | (10,873 | ) | — | ||||
Accounts payable | 24,851 | 150,153 | |||||
Accrued expenses | 33,295 | (130,257 | ) | ||||
Accrued post-retirement benefits (related party) | (25,473 | ) | (6,360 | ) | |||
Change in operating lease liability | (82,910 | ) | — | ||||
Deferred revenue | (333 | ) | 17,106 | ||||
Liabilities of discontinued operations | (3,439 | ) | 278 | ||||
Net cash provided by operating activities | 7,166 | 11,832 | |||||
Cash Flows from Investing Activities: | |||||||
Purchase of equipment | — | (6,506 | ) | ||||
Net cash used in investing activities | — | (6,506 | ) | ||||
Cash Flows from Financing Activities: | |||||||
Repayment of note payable | (822 | ) | (506 | ) | |||
Proceeds from line of credit | — | 36,575 | |||||
Net cash (used in) provided by financing activities | (822 | ) | 36,069 | ||||
Net increase in cash, cash equivalents and restricted cash | 6,344 | 41,395 | |||||
Cash, cash equivalents and restricted cash, beginning of year | 662,878 | 1,124,002 | |||||
Cash, cash equivalents and restricted cash, end of year | $ | 669,222 | $ | 1,165,397 | |||
Cash, cash equivalents and restricted cash consist of the following: | |||||||
End of period | |||||||
Cash and cash equivalents | $ | 415,818 | $ | 914,616 | |||
Restricted cash | 253,404 | 250,781 | |||||
$ | 669,222 | $ | 1,165,397 | ||||
Beginning of period | |||||||
Cash and cash equivalents | 409,743 | 874,002 | |||||
Restricted cash | 253,135 | 250,000 | |||||
$ | 662,878 | $ | 1,124,002 |
Supplemental Schedule of Cash Flow Information: | |||||||
Interest paid | $ | 5,827 | $ | 35,648 | |||
Non Cash Finance Activities | |||||||
Record right-of-use assets per ASC 842, net of deferred rent reclassification | $ | 1,137,878 | $ | — | |||
Record lease liability per ASC 842 | $ | 1,208,466 | $ | — |
• | Unsatisfied Performance Obligations - all performance obligations relate to contracts with a duration of less than one year, the Company has elected to apply the optional exemption provided in ASC 606 and therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. |
• | Contract Costs - all incremental customer contract acquisition costs are expensed as they are incurred as the amortization period of the asset that the Company otherwise would have recognized is one year or less in |
• | Significant Financing Component - the Company does not adjust the promised amount of consideration for the effects of a significant financing component as the Company expects, at contract inception, that the period between when the entity transfers a promised good or service to a customer and when the customer pays for that good or service will be one year or less. |
• | Sales Tax Exclusion from the Transaction Price - the Company excludes from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from the customer. |
• | Shipping and Handling Activities - the Company elected to account for shipping and handling activities as a fulfillment cost rather than as a separate performance obligation. |
• | Portfolio Approach - the Company applied the Portfolio Approach to contract reviews within its identified revenue streams that have similar characteristics and the Company believes this approach would not differ materially than if applying Topic 606 to each individual contract. |
(in thousands) | Three Months Ended September 30, | |||||||
2019 | 2018 | |||||||
Beginning of Period | $ | 427 | $ | 481 | ||||
Additions | 235 | 252 | ||||||
Revenue Recognized | 235 | 235 | ||||||
End of Period | $ | 426 | $ | 498 |
For the Three Months Ended September 30, | |||||||||
2019 | 2018 | ||||||||
Numerator: | |||||||||
Numerator for basic earnings (loss) per share: | |||||||||
Net income (loss) | $ | 621,373 | $ | (47,736 | ) | ||||
Undeclared dividends on preferred stock | 13,006 | 13,005 | |||||||
Net income (loss) applicable to common shareholders | $ | 608,367 | $ | (60,741 | ) | ||||
Numerator for diluted earnings per share: | |||||||||
Net income (loss) applicable to common shareholders | $ | 608,367 | $ | (60,741 | ) | ||||
Undeclared dividends on preferred stock | 13,006 | — | |||||||
Net income (loss) | $ | 621,373 | $ | (60,741 | ) | ||||
Denominator: | |||||||||
Denominator for basic earnings (loss) per share - weighted average shares outstanding | 7,415,329 | 7,415,329 | |||||||
Weighted average preferred stock converted to common stock | 4,773,120 | — | |||||||
Denominator for diluted earnings (loss) per share - weighted average and assumed conversion | 12,188,449 | — | 7,415,329 | ||||||
Net income (loss) per share: | |||||||||
Basic net income (loss) per share | $ | 0.08 | $ | (0.01 | ) | ||||
Diluted net income (loss) per share | $ | 0.05 | $ | (0.01 | ) |
For the Three Months Ended September 30, | ||||||
2019 | 2018 | |||||
Stock options | 213,000 | 213,000 | ||||
Convertible preferred stock | — | 4,515,820 | ||||
Total potential dilutive securities not included in income per share | 213,000 | 4,728,820 |
September 30, | June 30, | ||||
(in thousands) | 2019 | 2019 | |||
Inventories, net: | |||||
Raw Material | 706 | 875 | |||
Work-In-Process | 231 | 225 | |||
Finished Goods | 964 | 779 | |||
Total | 1,901 | 1,879 |
September 30, | June 30, | ||||||
2019 | 2019 | ||||||
Assets | |||||||
Total assets | $ | — | $ | — | |||
Liabilities | |||||||
Accrued lease termination costs | 87 | 91 | |||||
Total liabilities | 87 | 91 | |||||
Net liabilities of discontinued operations | $ | (87 | ) | $ | (91 | ) |
( in thousands) | For the Three Months Ended September 30, | |||||||||||||
2019 | 2018 | |||||||||||||
Domestic | $ | 1,467 | 64.1 | % | $ | 1,469 | 65.1 | % | ||||||
Foreign | 821 | 35.9 | % | 789 | 34.9 | % | ||||||||
Total | $ | 2,288 | 100.0 | % | $ | 2,258 | 100.0 | % |
Three Months Ended | ||||
September 30, 2019 | ||||
Operating lease costs: | ||||
Fixed | 104,449 | |||
Total: | $ | 104,449 |
Three Months Ended | ||||
September 30, 2019 | ||||
Cash paid for amounts included in the measurement of lease liabilities | ||||
Operating cash flows for operating leases | 99,569 | |||
Total | $ | 99,569 |
September 30, | ||||||
Leases (operating) | Classification on the Balance Sheet | 2019 | ||||
Assets | ||||||
Operating lease ROU assets | Right-of-use asset | $ | 1,055,682 | |||
Liabilities | ||||||
Current | Current portion of operating lease liabilities | 281,085 | ||||
Non-current | Operating lease liabilities | 844,471 |
Operating | ||||
2020 (excluding the three months ending September 30, 2019) | $ | 260,858 | ||
2021 | 276,894 | |||
2022 | 260,628 | |||
2023 | 189,848 | |||
2024 | 189,790 | |||
Thereafter | 96,830 | |||
Total lease payments | 1,274,848 | |||
Less interest | 149,292 | |||
Present value of lease liabilities | $ | 1,125,556 |
September 30, | |||
2019 | |||
Weighted-average remaining lease terms (years) | |||
Operating leases | 4.48 | ||
Weighted-average discount rate | |||
Operating leases | 5.65 | % |
Operating | ||||
2019 | $ | 356,414 | ||
2020 | 272,881 | |||
2021 | 256,311 | |||
2022 | 188,755 | |||
2023 | 189,790 | |||
Thereafter | 96,830 | |||
Total lease payments | $ | 1,360,981 |
• | Consolidated net revenue increased approximately $30,000 or 1.3%, to $2,288,000 during the three months ended September 30, 2019 as compared to same period of the last fiscal year. The increase in net revenue is attributed to an increase in sales of Trek products of $92,000 mainly due to back ordered items shipped in the three months ended September 30, 2019. The increase is offset by a decrease in EMI's total product sales of $56,000, related to a decrease in ophthalmic fundus photography system product sales of $55,000 and a decrease in revenue from service plans of $1,000, and a decrease in sales in Sonomed's ultrasound products of $6,000. |
• | Consolidated cost of goods sold totaled approximately $1,177,000, or 51.4%, of total revenue or the three months ended September 30 2019, as compared to $1,203,000, or 53.3%, of total revenue for the three months of the last fiscal year. The decrease of 1.9% in cost of goods sold as a percentage of total revenue is mainly due to changes in product sales mix and improved pricing. |
• | Consolidated marketing, general and administrative expenses decreased $3,000, or 0.3%, to $999,000 for the three months ended September 30 2019, as compared to the same period of last fiscal year. There are no significant changes for the marketing, general and administrate expenses. |
• | Consolidated research and development expenses increased $150,000 or 156.3%, to $246,000 for the three months ended September 30 2019, as compared to the same period of last fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The increase in research and development expense is mainly due to expense for AXIS software development work and ultrasound certification costs incurred during the three months ended September 30, 2019. |
For the Three Months Ended September 30, | |||||||||||
2019 | 2018 | % Change | |||||||||
Net Revenue: | |||||||||||
Products | $ | 2,053 | $ | 2,022 | 1.5 | % | |||||
Service plans | $ | 235 | $ | 236 | (0.4 | )% | |||||
Total | $ | 2,288 | $ | 2,258 | 1.3 | % |
For the Three Months Ended September 30, | ||||||||||||||
2019 | 2018 | |||||||||||||
Domestic | $ | 1,467 | 64.1 | % | $ | 1,469 | 65.1 | % | ||||||
Foreign | 821 | 35.9 | % | 789 | 34.9 | % | ||||||||
Total | $ | 2,288 | 100.0 | % | $ | 2,258 | 100.0 | % |
For the Three Months Ended September 30, | ||||||||||||||
2019 | % | 2018 | % | |||||||||||
Cost of Goods Sold: | ||||||||||||||
$ | 1,177 | 51.4 | % | $ | 1,203 | 53.3 | % | |||||||
Total | $ | 1,177 | 51.4 | % | $ | 1,203 | 53.3 | % |
For the Three Months Ended September 30, | |||||||||||
2019 | 2018 | % Change | |||||||||
Marketing, General and Administrative: | |||||||||||
$ | 999 | $ | 1,002 | (0.3 | )% | ||||||
Total | $ | 999 | $ | 1,002 | (0.3 | )% |
For the Three Months Ended September 30, | |||||||||||
2019 | 2018 | % Change | |||||||||
Research and Development: | |||||||||||
$ | 246 | $ | 96 | 156.3 | % | ||||||
Total | $ | 246 | $ | 96 | 156.3 | % |
September 30, | June 30, | |||
2019 | 2019 | |||
Current Ratio: | ||||
Current assets | $4,153 | $4,261 | ||
Less: Current liabilities | 2,432 | 2,260 | ||
Working capital | $1,721 | $2,001 | ||
Current ratio | 1.71 to 1 | 1.89 to 1 | ||
Debt to Total Capital Ratio: | ||||
Line of credit, note payable and lease liabilities | $1,345 | $220 | ||
Total debt | 1,345 | 220 | ||
Total equity | 2,784 | 2,162 | ||
Total capital | $4,129 | $2,382 | ||
Total debt to total capital | 32.6% | 9.2% |
Escalon Medical Corp. | ||||
(Registrant) | ||||
Date: November 14, 2019 | By: | /s/ Richard J. DePiano, Jr. | ||
Richard J. DePiano, Jr. | ||||
Chief Executive Officer | ||||
Date: November 14, 2019 | By: | /s/ Mark Wallace | ||
Mark Wallace | ||||
Chief Operating Officer and Principal Accounting & Financial Officer |
1. | I have reviewed this annual report on Form 10-Q of Escalon Medical Corp.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
/s/ Richard J. DePiano Jr. | |
Richard J. DePiano Jr. | |
Chief Executive Officer | |
Date: November 14, 2019 |
1. | I have reviewed this annual report on Form 10-Q of Escalon Medical Corp.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
/s/ Mark Wallace | |
Mark Wallace | |
Date: November 14, 2019 |
1. | The Quarterly Report of Escalon Medical Corp. on Form 10Q for the quarterly period ended September 30, 2019 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Richard J. DePiano Jr. | |
Richard J. DePiano Jr. | |
Chief Executive Officer |
1. | The Quarterly Report of Escalon Medical Corp. on Form 10-Q for the quarterly period ended September 30, 2019 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Mark Wallace | |
Mark Wallace | |
Chief Operating Officer and Principal Accounting & Financial Officer |
Retirement and post retirement plans (Tables) |
3 Months Ended | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2019 | ||||||||||
Retirement Benefits [Abstract] | ||||||||||
Schedule of Changes in Fair Value of Plan Assets [Table Text Block] |
Significant Accounting Policies (Policies) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restrictions on Cash and Cash Equivalents [Table Text Block] | As of September 30, 2019 and June 30, 2019 restricted cash included $253,404 and $253,135 respectively, which was pursuant to the requirements in the TD Bank Loan entered into June 2018 (see Note 7). |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Foreign Currency Transactions and Translations Policy [Policy Text Block] | The Company's functional currency is the US dollar. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred. Foreign currency transaction gains or losses included in net income (loss) were immaterial for the three months ended September 30, 2019 and 2018. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principles of Consolidation | The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Use of Estimates | The preparation of financial statements in conformity with accounting principles generally affected in the US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash and Cash Equivalents | For the purposes of reporting cash flows, the Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and highly liquid investments with original maturities of 90 days or less to be cash and cash equivalents. From time to time cash balances exceed federal insurance limits. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Financial Instruments | The carrying amounts for cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term maturity. The carrying amount of the accrued post retirement benefits approximates fair value since the Company utilizes approximate current market interest rates to calculate the liability. The Company determined that the carrying amount of the note payable and lease liabilities approximates fair value since such debt borrowing bears interest at the approximate current market rate. While the Company believes the carrying value of the assets and liabilities are reasonable, considerable judgment is used to develop estimates of fair value; thus the estimates are not necessarily indicative of the amounts that could be realized in a current market exchange. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue Recognition | Revenue Recognition The Company recognizes revenue when its performance obligations with its customers have been satisfied. At contract inception, the Company determines if the contract is within the scope of Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, and then evaluates the contract using the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. The Company generates product revenue from the sale of medical device products and the sale and installation of the Company's AXIS image management system software. Revenue for service plans relate to the customer care plans for the Company’s equipment and AXIS image management system software. Revenue is recognized upon transfer of control of the promised goods or services to the customer for an amount that reflects the consideration that the Company expects to be entitled in exchange for those goods or services. The Company’s performance obligations are for product sales, installation of AXIS image management system software and customer care plans. The performance obligations are determined at contract inception based upon promises within the contract that are distinct. The product sales and installation of AXIS image management system software performance obligations are satisfied at a point in time, which is upon shipment for product sales and upon successful installation for the AXIS image management system. The performance obligation for customer care plans is satisfied over time as the customer receives and consumes the Company’s services. The Company invoices its customers upon shipment for product sales. For the installation of AXIS image management system software and customer care plans, the Company invoices its customers upon successful installation. Invoice payments are generally due within 30 days of invoice date. The transaction price is determined based on fixed consideration in the Company’s customer contracts and is recorded net of variable consideration. In determining the transaction price, a significant financing component does not exist since the timing from when the Company invoices its customers to when payment is received as it is less than one year. Revenue for product sales and installation of AXIS image management system software is recognized when delivered or installed. The customer care plan revenues are recognized proportionately over the service period, which is a 12-month period. The Company has elected the following practical expedients in applying ASC 606:
Deferred Revenues The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the customer care plans for a 12-month period. The consideration received is recognized monthly over the service period.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory | Inventories include freight-in materials, labor and overhead costs, and are stated at the lower of cost (first-in, first-out) or net realizable value. The Company writes down its inventories as it becomes aware of any situation whereas the carrying amount exceeds the estimated realizable value based on assumptions about future demands and market conditions. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts Receivable | Accounts receivable are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company recorded an allowance for doubtful accounts of approximately $111,000 as of September 30, 2019 and June 30, 2019. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intangible Assets | ntangible assets deemed to have indefinite lives (including trademark and trade names) are not amortized but, instead, are subject to an annual impairment assessment. Additionally, if events or conditions were to indicate the carrying value or a reporting unit may not be recoverable, the Company would evaluate the other intangible assets for impairment at that time. Long-lived assets including intangible assets deemed to have finite lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Impairment indicators include, among other conditions, cash flow deficits, historic or anticipated declines in revenue or operating profit or material adverse changes in the business climate that indicate that the carrying amount of an asset may be impaired. When impairment indicators are present, the recoverability of the asset is measured by comparing the carrying value of the asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the projected undiscounted cash flows from the asset are less than the carrying value of the asset the asset is considered to be impaired. The impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. During the three months ended September 30, 2019 and September 30, 2018, no impairments were recorded. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued Warranties | The Company provides a limited one-year warranty against manufacturer’s defects on its products sold to customers. The Company’s standard warranties require the Company to repair or replace, at the Company’s discretion, defective parts during such warranty period. The Company accrues for its product warranty liabilities based on estimates of costs to be incurred during the warranty period, based on historical repair information for warranty costs. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Income (loss) Per Share | Earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the year. All outstanding stock options are considered potential common stock. All outstanding convertible preferred stock are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. The dilutive effect, if any, of stock options is calculated using the treasury stock method. As of September, 2019 and 2018, the average market prices for the three-month period then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the the stock options would be anti-dilutive. In addition, since the effect of common stock equivalents is anti-dilutive with respect to losses, the convertible preferred stock has also been excluded from the Company’s computation of loss per common for the three-month period ended September 30, 2018. Therefore, basic and diluted loss per common share for the three-month period ended September 30, 2018 are the same. For the three-month period ended September 30, 2019, the if-converted method was used for the convertible preferred stock to calculate the dilutive earnings per share.
The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.
Earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the year. All outstanding stock options are considered potential common stock. All outstanding convertible preferred stock are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. The dilutive effect, if any, of stock options is calculated using the treasury stock method. As of September, 2019 and 2018, the average market prices for the three-month period then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the the stock options would be anti-dilutive. In addition, since the effect of common stock equivalents is anti-dilutive with respect to losses, the convertible preferred stock has also been excluded from the Company’s computation of loss per common for the three-month period ended September 30, 2018. Therefore, basic and diluted loss per common share for the three-month period ended September 30, 2018 are the same. For the three-month period ended September 30, 2019, the if-converted method was used for the convertible preferred stock to calculate the dilutive earnings per share.
The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Taxes | The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the unaudited condensed consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of September 30, 2019 and June 30, 2019, the Company has a fully recorded valuation allowance against its deferred tax assets. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of September 30, 2019 and June 30, 2019, no accrued interest or penalties were required to be included on the related tax liability line in the unaudited condensed consolidated balance sheets. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lessee, Leases [Policy Text Block] | The Company determines if an arrangement is a lease at the inception of a contract. Operating lease right-of-use ("ROU") assets are included in right-of-use assets on the unaudited condensed consolidated balance sheets. The current and long-term components of operating lease liabilities are included in the current portion of operating lease liabilities and operating lease liabilities, net of current portion, respectively on the unaudited condensed consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. Certain leases may include options to extend or terminate the lease. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reclassification, Policy [Policy Text Block] | Reclassifications Lease deposits of $51,915 in the June 30, 2019 consolidated balance sheet has been reclassed from other current assets to the other assets be conformity with the current period presentation. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
New Accounting Pronouncements | Recently Issued Accounting Standards The Company considers the applicability and impact of all accounting standards updates ("ASUs"). Management periodically reviews new accounting standards that are issued. New Accounting Pronouncements Recently Adopted Effective July 1, 2019, the Company adopted ASU No. 2016-02, Leases (Topic 842), using the cumulative effect adjustment method and elected certain practical expedients allowed under the standard. Upon adoption, the Company recognized ROU assets and a lease liability of $1,137,878 and $1,208,466 respectively. The adoption didn't materially impact the Company's unaudited condensed consolidated statements of operations or cash flows. See Note 11 for additional information on the Company's adoption of this standard. In June 2018 the FASB issued ASU 2018-07 Improvements to Nonemployee Share-Based Payment Accounting (Topic 718) that expands the scope to include share-based payment transactions for acquiring goods and services from non-employees. An entity should apply the requirements to nonemployee awards except for certain exemptions specified in the amendment. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted. The adoption of ASU 2018-07 did not have a material impact on the Company's unaudited condensed consolidated financial statements. New Accounting Pronouncements Not yet Adopted In June 2016 the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which adds a new Topic 326 to the Codification and removes the thresholds that companies apply to measure credit losses on financial instruments measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities. The guidance in ASU 2016-13 is effective for “public business entities,” as defined, that are SEC filers for fiscal years and for interim periods with those fiscal years beginning after December 15, 2019. Early adoption of the guidance is permitted for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years.The adoption of this standard is not expected to have a material impact to the Company’s unaudited condensed consolidated financial statements. |
Related Party Transactions |
3 Months Ended |
---|---|
Sep. 30, 2019 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Related Party Transactions and Preferred Stock Richard J. DePiano Sr., (“Mr. DePiano Sr.”), the Company’s Chairman, participated in an accounts receivable factoring program that was implemented by the Company. Under the program, Mr. DePiano Sr. advanced the Company $645,000 prior to the Debt Exchange Agreement noted below. Interest on the transaction was 1.25% per month. The transactions excluded fees typically charged by the factoring agent and provided much needed liquidity to the Company. There was no related party interest expense for the three months ended ended September 30, 2019 and 2018. As of September 30, 2019 and June 30, 2019, accrued interest of $112,389 was payable under the factoring agreement. On February 14, 2018, the Company entered into a Debt Exchange Agreement (the “Exchange Agreement”) with Mr. DePiano Sr., the Company's Chairman and DP Associates Inc. Profit-Sharing Plan of which Mr. DePiano Sr. is the sole owner and sole trustee (the “Holders”). Pursuant to the terms of the Exchange Agreement, effective February 15, 2018, the Holders exchanged a total of $645,000 principal amount of debt related to the accounts receivable factoring program the Company owes the Holders for 2,000,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”). Each share of Preferred Stock entitles the Holder thereof to 13 votes per share and will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders. As a result of this voting power, the Holders as of September 30, 2019 beneficially own approximately 77.81% of the voting power on all actions to be taken by the Company’s shareholders. Subject to the terms and conditions of Preferred Stock, the holder of any share or shares of the Preferred Stock has the right, at its option at any time, to convert each such share of Preferred Stock (except that, upon any liquidation of the Company, the right of conversion will terminate at the close of business on the business day fixed for payment of the amounts distributable on the Preferred Stock) into 2.15 shares of Common Stock (the “Conversion Ratio”). The Conversion Ratio is subject to standard provisions for adjustment in the event of a subdivision or combination of the Company’s Common Stock and upon any reorganization or reclassification of the capital stock of the Company. If the Holders were to convert their shares of Preferred Stock into Common Stock at the Conversion Ratio the Holders would receive a total of 4,300,000 shares of Common Stock, or approximately 36.70% of the then outstanding shares of Common Stock assuming such conversion. Each outstanding share of the Preferred Stock accrues dividends calculated cumulatively at the annual rate of $.0258 per share (such amount subject to equitable adjustment in the event of any stock dividend, stock split, combination, reclassification other similar event), payable upon the earlier of (i) a liquidation, dissolution or winding up of the Company or (ii) conversion of the Preferred Stock into Common Stock. Upon either of such events, all such accrued and unpaid dividends, whether or not earned or declared, to and until the date of such event, will become immediately due and payable and will be paid in full. The dividends payable to the holders of the Preferred Stock is payable in cash or, at the election of any such holder, in a number of additional shares of Common Stock equal to the amount of the dividend expressed in dollars divided by the then applicable Conversion Ratio, described above. As of September 30, 2019 and June 30, 2019 the cumulative dividends payable is $83,973 ($0.0420 per share) and $70,968 ($0.0355 per share), respectively. Mr. DePiano Sr. passed away on October 3, 2019 and left a will by which he appointed Richard J. DePiano, Jr., the Chief Executive Officer of the Company, as executor. When Mr. DePiano, Jr. qualifies as executor, which is expected to take place on or before November 15, 2019, he will have control over the listed shares in his capacity as executor of Mr. DePiano Sr.'s estate. |
Line of credit (Details) - USD ($) |
3 Months Ended | ||||
---|---|---|---|---|---|
Sep. 30, 2019 |
Sep. 30, 2018 |
Jun. 30, 2019 |
Jun. 30, 2018 |
Jun. 29, 2018 |
|
Line of Credit Facility [Line Items] | |||||
Line of Credit Facility, Fair Value of Amount Outstanding | $ 201,575 | ||||
Line of Credit Facility, Periodic Payment, Interest | $ 3,639 | $ 6,580 | |||
Line of Credit Facility, Interest Rate at Period End | 6.24% | ||||
Repayments of Lines of Credit | 201,575 | ||||
Accrued expenses | $ 619,413 | $ 656,707 | |||
Line of Credit [Member] | |||||
Line of Credit Facility [Line Items] | |||||
Repayments of Lines of Credit | 165,000 | ||||
Interest paid | 2,579 | ||||
General and Administrative Expense | 1,000 | ||||
Line Of Credit Facility, Prime Plus Fee | 1,895 | ||||
Accrued expenses | $ 28,797 | ||||
Notes Payable to Banks [Member] | |||||
Line of Credit Facility [Line Items] | |||||
Notes Payable to Bank | $ 250,000 | ||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | ||||
Debt Instrument, Basis Spread on Variable Rate | 74.00% | ||||
Debt Instrument, Interest Rate During Period | 5.74% | ||||
Line of Credit Facility, Collateral Fees, Amount | $ 250,000 |
Label | Element | Value |
---|---|---|
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $ 1,124,002 |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | 662,878 |
Cash | us-gaap_Cash | 1,124,002 |
Cash | us-gaap_Cash | $ 662,878 |
Significant Accounting Policies |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Significant Accounting Policies | Summary of Significant Accounting Policies Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with accounting principles generally affected in the US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents For the purposes of reporting cash flows, the Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and highly liquid investments with original maturities of 90 days or less to be cash and cash equivalents. From time to time cash balances exceed federal insurance limits. Restricted Cash As of September 30, 2019 and June 30, 2019 restricted cash included $253,404 and $253,135 respectively, which was pursuant to the requirements in the TD Bank Loan entered into June 2018 (see Note 7). Foreign Currency Translation The Company's functional currency is the US dollar. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred. Foreign currency transaction gains or losses included in net income (loss) were immaterial for the three months ended September 30, 2019 and 2018. Accounts Receivable Accounts receivable are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company recorded an allowance for doubtful accounts of approximately $111,000 as of September 30, 2019 and June 30, 2019. Inventories Inventories include freight-in materials, labor and overhead costs, and are stated at the lower of cost (first-in, first-out) or net realizable value. The Company writes down its inventories as it becomes aware of any situation whereas the carrying amount exceeds the estimated realizable value based on assumptions about future demands and market conditions. Intangible Assets and Long-Lived Assets Intangible assets deemed to have indefinite lives (including trademark and trade names) are not amortized but, instead, are subject to an annual impairment assessment. Additionally, if events or conditions were to indicate the carrying value or a reporting unit may not be recoverable, the Company would evaluate the other intangible assets for impairment at that time. Long-lived assets including intangible assets deemed to have finite lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Impairment indicators include, among other conditions, cash flow deficits, historic or anticipated declines in revenue or operating profit or material adverse changes in the business climate that indicate that the carrying amount of an asset may be impaired. When impairment indicators are present, the recoverability of the asset is measured by comparing the carrying value of the asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the projected undiscounted cash flows from the asset are less than the carrying value of the asset the asset is considered to be impaired. The impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. During the three months ended September 30, 2019 and September 30, 2018, no impairments were recorded. Accrued Warranties The Company provides a limited one-year warranty against manufacturer’s defects on its products sold to customers. The Company’s standard warranties require the Company to repair or replace, at the Company’s discretion, defective parts during such warranty period. The Company accrues for its product warranty liabilities based on estimates of costs to be incurred during the warranty period, based on historical repair information for warranty costs. Fair Value of Financial Instruments The carrying amounts for cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term maturity. The carrying amount of the accrued post retirement benefits approximates fair value since the Company utilizes approximate current market interest rates to calculate the liability. The Company determined that the carrying amount of the note payable and lease liabilities approximates fair value since such debt borrowing bears interest at the approximate current market rate. While the Company believes the carrying value of the assets and liabilities are reasonable, considerable judgment is used to develop estimates of fair value; thus the estimates are not necessarily indicative of the amounts that could be realized in a current market exchange. Revenue Recognition The Company recognizes revenue when its performance obligations with its customers have been satisfied. At contract inception, the Company determines if the contract is within the scope of Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, and then evaluates the contract using the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. The Company generates product revenue from the sale of medical device products and the sale and installation of the Company's AXIS image management system software. Revenue for service plans relate to the customer care plans for the Company’s equipment and AXIS image management system software. Revenue is recognized upon transfer of control of the promised goods or services to the customer for an amount that reflects the consideration that the Company expects to be entitled in exchange for those goods or services. The Company’s performance obligations are for product sales, installation of AXIS image management system software and customer care plans. The performance obligations are determined at contract inception based upon promises within the contract that are distinct. The product sales and installation of AXIS image management system software performance obligations are satisfied at a point in time, which is upon shipment for product sales and upon successful installation for the AXIS image management system. The performance obligation for customer care plans is satisfied over time as the customer receives and consumes the Company’s services. The Company invoices its customers upon shipment for product sales. For the installation of AXIS image management system software and customer care plans, the Company invoices its customers upon successful installation. Invoice payments are generally due within 30 days of invoice date. The transaction price is determined based on fixed consideration in the Company’s customer contracts and is recorded net of variable consideration. In determining the transaction price, a significant financing component does not exist since the timing from when the Company invoices its customers to when payment is received as it is less than one year. Revenue for product sales and installation of AXIS image management system software is recognized when delivered or installed. The customer care plan revenues are recognized proportionately over the service period, which is a 12-month period. The Company has elected the following practical expedients in applying ASC 606:
Deferred Revenues The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the customer care plans for a 12-month period. The consideration received is recognized monthly over the service period.
Earnings (Loss) Per Share Earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the year. All outstanding stock options are considered potential common stock. All outstanding convertible preferred stock are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. The dilutive effect, if any, of stock options is calculated using the treasury stock method. As of September, 2019 and 2018, the average market prices for the three-month period then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the the stock options would be anti-dilutive. In addition, since the effect of common stock equivalents is anti-dilutive with respect to losses, the convertible preferred stock has also been excluded from the Company’s computation of loss per common for the three-month period ended September 30, 2018. Therefore, basic and diluted loss per common share for the three-month period ended September 30, 2018 are the same. For the three-month period ended September 30, 2019, the if-converted method was used for the convertible preferred stock to calculate the dilutive earnings per share.
The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.
Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the unaudited condensed consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of September 30, 2019 and June 30, 2019, the Company has a fully recorded valuation allowance against its deferred tax assets. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of September 30, 2019 and June 30, 2019, no accrued interest or penalties were required to be included on the related tax liability line in the unaudited condensed consolidated balance sheets. Leases The Company determines if an arrangement is a lease at the inception of a contract. Operating lease right-of-use ("ROU") assets are included in right-of-use assets on the unaudited condensed consolidated balance sheets. The current and long-term components of operating lease liabilities are included in the current portion of operating lease liabilities and operating lease liabilities, net of current portion, respectively on the unaudited condensed consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. Certain leases may include options to extend or terminate the lease. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Reclassifications Lease deposits of $51,915 in the June 30, 2019 consolidated balance sheet has been reclassed from other current assets to the other assets be conformity with the current period presentation. New Accounting Pronouncements Recently Issued Accounting Standards The Company considers the applicability and impact of all accounting standards updates ("ASUs"). Management periodically reviews new accounting standards that are issued. New Accounting Pronouncements Recently Adopted Effective July 1, 2019, the Company adopted ASU No. 2016-02, Leases (Topic 842), using the cumulative effect adjustment method and elected certain practical expedients allowed under the standard. Upon adoption, the Company recognized ROU assets and a lease liability of $1,137,878 and $1,208,466 respectively. The adoption didn't materially impact the Company's unaudited condensed consolidated statements of operations or cash flows. See Note 11 for additional information on the Company's adoption of this standard. In June 2018 the FASB issued ASU 2018-07 Improvements to Nonemployee Share-Based Payment Accounting (Topic 718) that expands the scope to include share-based payment transactions for acquiring goods and services from non-employees. An entity should apply the requirements to nonemployee awards except for certain exemptions specified in the amendment. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted. The adoption of ASU 2018-07 did not have a material impact on the Company's unaudited condensed consolidated financial statements. New Accounting Pronouncements Not yet Adopted In June 2016 the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which adds a new Topic 326 to the Codification and removes the thresholds that companies apply to measure credit losses on financial instruments measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities. The guidance in ASU 2016-13 is effective for “public business entities,” as defined, that are SEC filers for fiscal years and for interim periods with those fiscal years beginning after December 15, 2019. Early adoption of the guidance is permitted for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years.The adoption of this standard is not expected to have a material impact to the Company’s unaudited condensed consolidated financial statements. |
Document And Entity Information |
3 Months Ended |
---|---|
Sep. 30, 2019
shares
| |
Document And Entity Information [Abstract] | |
Entity Registrant Name | ESCALON MEDICAL CORP. |
Entity Central Index Key | 0000862668 |
Current Fiscal Year End Date | --06-30 |
Entity Filer Category | Non-accelerated Filer |
Document Type | 10-Q |
Document Period End Date | Sep. 30, 2019 |
Document Fiscal Year Focus | 2020 |
Document Fiscal Period Focus | Q1 |
Amendment Flag | false |
Entity Small Business | true |
Entity Emerging Growth Company | false |
Entity Shell Company | false |
Entity Common Stock, Shares Outstanding | 7,415,329 |
Entity Current Reporting Status | Yes |
Significant Accounting Policies (Cash and Cash Equivalents) (Details) - USD ($) |
3 Months Ended | |||
---|---|---|---|---|
Sep. 30, 2019 |
Jun. 30, 2019 |
Sep. 30, 2018 |
Jun. 30, 2018 |
|
Accounting Policies [Abstract] | ||||
Restricted Cash | $ 253,404 | $ 253,135 | $ 250,781 | $ 250,000 |
Maximum maturity of highly liquid investments, period | 90 days |
Significant Accounting Policies (Net Income (loss) Per Share) (Details) - USD ($) |
3 Months Ended | |
---|---|---|
Sep. 30, 2019 |
Sep. 30, 2018 |
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Net income (loss) | $ 621,373 | $ (47,736) |
Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic | $ 608,367 | $ (60,741) |
Basic Weighted average shares outstanding | 7,415,329 | 7,415,329.0 |
Weighted average shares - diluted | 12,188,449 | 7,415,329 |
Going concern (Details) - USD ($) |
Sep. 30, 2019 |
Jun. 30, 2019 |
---|---|---|
Going concern [Abstract] | ||
Retained Earnings (Accumulated Deficit) | $ (67,570,846) | $ (68,192,219) |
Retirement and post retirement plans (Notes) |
3 Months Ended | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2019 | ||||||||||
Retirement Benefits [Abstract] | ||||||||||
Postemployment Benefit Plans, Policy [Policy Text Block] | Retirement and Post-Retirement Plans On June 23, 2005 the Company entered into a Supplemental Executive Retirement Benefit Agreement with its Chairman, Richard DePiano, Sr. (Mr. DePiano Sr.). The agreement provided for the payment of supplemental retirement benefits to the covered executive in the event of the covered executive’s termination of services. In January 2013 the covered executive retired and the Company was obligated to pay the executive $8,491 per month for life, with payments commencing the month after retirement. As of June 30, 2019 approximately $792,000 was accrued for Mr. DePiano Sr.'s retirement benefits. The amount represented the approximate present value of the supplemental retirement benefits awarded using a discount rate of 4.5% as of June 30, 2019. Mr. DePiano Sr. passed away on October 3, 2019. According to the agreement, the benefits terminate upon Mr. DePiano Sr.'s death. Therefore, the Company recognized a gain with the termination of the retirement benefit obligation of $758,000, which has been reported as other income for the three-month period ended September 30, 2019. The remaining $8,491 accrual as of September 30, 2019 represents the final payment that was made on October 1, 2019. |
Discontinued operation (Notes) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] | Discontinued Operations BH Holdings, S.A.S ("BHH") Drew Scientific, Inc. ("Drew"), an inactive subsidiary of the Company which was sold in 2012, has a controlling interest in BHH Holidngs, S.A.S ("BHH). On January 12, 2012 BHH, initiated the filing of an insolvency declaration with the Tribunal de Commerce de Rennes, France ("Commercial Court"). The Commercial Court on January 18, 2012 opened the liquidation proceedings with continuation of BHH's activity for three months and named an administrator to manage BHH. Since Drew no longer had a controlling financial interest in BHH it was deconsolidated in the December 31, 2011 quarterly unaudited condensed consolidated financial statements and prior period amounts are presented as discontinued operations. Assets and liabilities of discontinued operations of BHH included in the consolidated balance sheets are summarized as follows at September 30, 2019 and June 30, 2019 (in thousands):
During fiscal year 2015 the Company was informed by French Counsel that the total amount claimed by the BHH landlord in the liquidation of BHH was approximately $86,000. The Company did not have insight into the French liquidation process due to the Liquidator's reticence to communicate with the Company. As such, the Company had accrued the present value of the maximum amount potentially due under the lease guaranteed by the Company on behalf of BHH. The landlord's claim under liquidation of approximately $86,000 cannot be revisited by the landlord and can only be potentially increased by interest or sundry expenses. Beginning in 2016 any changes to this liability are included in continuing operations. As of September 30, 2019 and June 30, 2019 the liability was approximately $87,000 and $91,000, respectively. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BH Holdings, S.A.S [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disposal Groups, Including Discontinued Operations [Table Text Block] |
|
Concentration of credit risk (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] | Concentration of Credit Risk Credit Risk Financial Instruments, which potentially subject the Company to concentration of credit risk, consist principally of cash and cash equivalents, restricted cash and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely address the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral. Major Customer One customer accounted for more than 10% of net sales during the three months ended September 30, 2019. No customer accounted for more than 10% of net sales during the three months ended September 30, 2018. As of September 30, 2019 the Company had one customer that represents more than 10% of the total accounts receivable balance. As of June 30, 2019 the Company had no customer that represents more than 10% of the total accounts receivable balance. Major Supplier The Company's two largest suppliers accounted for 15% and 25% of the total purchase for the three-month period ended September 30, 2019. The Company's two largest suppliers accounted for of total purchases for more than 12% and 24% of total purchase for the three-month period ended September 30, 2018. Foreign Sales Domestic and international sales from continuing operations are as follows:
|
Concentration of credit risk (Details) - USD ($) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2019 |
Jun. 30, 2019 |
Sep. 30, 2018 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] | Concentration of Credit Risk Credit Risk Financial Instruments, which potentially subject the Company to concentration of credit risk, consist principally of cash and cash equivalents, restricted cash and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely address the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral. Major Customer One customer accounted for more than 10% of net sales during the three months ended September 30, 2019. No customer accounted for more than 10% of net sales during the three months ended September 30, 2018. As of September 30, 2019 the Company had one customer that represents more than 10% of the total accounts receivable balance. As of June 30, 2019 the Company had no customer that represents more than 10% of the total accounts receivable balance. Major Supplier The Company's two largest suppliers accounted for 15% and 25% of the total purchase for the three-month period ended September 30, 2019. The Company's two largest suppliers accounted for of total purchases for more than 12% and 24% of total purchase for the three-month period ended September 30, 2018. Foreign Sales Domestic and international sales from continuing operations are as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk, Customer | 0.1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk, Credit Risk, Financial Instruments | 0.10 | 0.1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Customer One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk, Supplier | 15% | 0.12 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Customer Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk, Supplier | 25% | 0.24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sales Revenue, Net [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk, Customer | 1 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts Receivable [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk, Customer | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk, Percentage | 100.00% | 100.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenues | $ 2,287,988 | $ 2,258,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Domestic [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk, Percentage | 64.10% | 65.06% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenues | $ 1,466,540 | $ 1,469,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
International [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk, Percentage | 35.90% | 34.94% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenues | $ 821,448 | $ 789,000 |
PF'\*LQ0)7.O(+&6>N"H!94X'+'?G5C+T[-F(RB^G&OY0490E>NP)P
MX2._K''N2@&8K:,2+7I-2\7-=ED95/S>V1:_V)T[^6'L5?_AXS/@.Q&WII/!
MF2O=\6Q?NG*NJ'8E?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M'%5J8I&1" ES6PS.0;QY&%B3U(-U)
M85_ND3>64GX/R@IJ7M+887#/[D[L[)$JO!:\EM'S4MU0E)TK?U.#;);,=!00$SD)%
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M-;=.5,AC4!]65TH%R)C.1H8KY/4U# AK&LL^Z0[P;"-KT]Q,:+LG\'U!+
M P04 " "I@&Y/KLEI1
1N_%TV\E@S$[?Y-_3'V[GNY, L/6OSBC>M+?,"H
M@9:-PCWKZ0F6?FXQ6IK_"E<0'AZ<^!JU%C9^43U:I^6BXJU(]CJO7,5UFO_<
MWBVT?0)="'0E'&(=,A>*SC\SQZK"Z F9^>P'%JXX/5)_-G5(QJ.(_[QYZ[/7
M*CVD!;D&H05SFC%TBUD1Q*NO)>A>B1/]CYXE^_QLUV(6^=D[BW1?(-\5R*-
M_DX@^]#C'B;_4(1L#E6"Z>(X653K4<51WF37B;VG\5+^P>=Q_\9,QY5%%^W\
MU<8+:+5VX*TD-WZ&>O_"UD! Z\+VSN_-/&=SX/2P/"&RON/J+U!+ P04
M" "I@&Y/P(:8'X0" #="0 &0 'AL+W=O
Q%G?LKW]O#
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M@Z"]G>IH_&LI_@%02P,$% @ J8!N3_.B3RPJ @ 508 !D !X;"]W
M;W)K*G$<
M&U,TW6^P.376E$,6)Z7,7OIK7G77<_^/3(
TZ(#N)O=\459E1>HZGBY)GOW"5M\%C.U5ME>\
M3\*@89?.-=O[%67?K-COG?
"
M!I-X>C"/CXZ//2(LM9GDA:#0+(OO&]=/ZA3UL)3LR8)&I(DPE(XV!H%#:A],
M)NQ]M TX7$KFIX;# LR"B
XO1@>A#M<>;$4-T%
M',?STR/\,*5?CJ?TRV$TF9_&\R/Z<$0?3DX/
M.&^"[66G\."A!MMV=@H*Z
MK*$ZFO(Y.NV6GW:$/J\=WUX:*B@
MAA>F7C#M2Y^_F4HO1Y>^?VYDU()^"P\Z0?43SQ[\$"&'(?(HO5;MI
M%O
2
MO#"M$J5G@DH)IHV4H%QP9!FZC-;0L@FF]-Y\-]^S'>TF VZ,V1(? D/1F7K6
MK3GLFF^1M]6<]K;L?KJ@)&NA/M=Z.MSVS>G!=Q)GI+'])NL!M#HJ2[KY1$G.
M&7:3^6W!8,^"<8BZ.J 0DCQJ/7-4$NW $H(UEHHDVYZ?$I5+W*CN.#79OLS3
M(V1^ZW7.,<<2T6UH??8/>97_,_'LXN^1[;_*&/@-&TL!ZV:Z4 UB84]+ 3OGKVV;*+175/AZZ90DL%7P9#WU,
M3"II8*G@F",?$Y-*VJM4QCXF)I4TL%1PS!,?$U-,VJMB3GU,3#%I8,7@F&<^
M)J:8M,>=S&.W,7C'Q!23]K27>4N<_B$*9INLM\U,A^IC8O;)/GA'